Navigation Links
Pharmaceutical Partnership Deal Terminations
Date:9/7/2011

r, Open-Label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed Flutiform HFA pMDI Study SKY2028-3-005 107

Table 73: Top Partnership Deal Terminations, Clinical Trial Details, Merck Vaccine Study in Healthy Adults, 2006 111

Table 74: Top Partnership Deal Terminations, Clinical Trial Details, Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant, 2006-2007 112

Table 75: Top Partnership Deal Terminations, Clinical Trial Details, Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery, 2007-2014 112

Table 76: Top Partnership Deal Terminations, Clinical Trial Details, V710 Clinical Study in Healthy Male Japanese Subjects, 2008 113

Table 77: Top Partnership Deal Terminations, Clinical Trial Details, A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis, 2008-2010 113

Table 78: Top Partnership Deal Terminations, Merck-Intercell Licensing Agreement, Deal Value ($m), 2004 114

1.2 List of Figures

Figure 1: Top Partnership Deal Terminations, Licensing Strategies in Large Pharmaceutical Companies, Pharmaceutical Licensing Life Cycle, 2011 10

Figure 2: Top Partnership Deal Terminations, Reasons for Deal Terminations, 2010-2011 12

Figure 3: Top Partnership Deal Terminations, Therapeutic Areas, 2010-2011 13

Figure 4: Top Partnership Deal Terminations, Comparative Analysis of Deal Values of the Top Terminated Deals, 2010-2011 14

Figure 5: Top Partnership Deal Terminations, GlaxoSmithKline Terminates Licensing Agreement with Actelion for Almorexant, 2011 16

Figure 6: Top Partnership Deal Terminations, GlaxoSmithKline Terminates Co-Development Agreement with Targacept for Development of Neuronal Nicotinic Receptor Therapeutics, 2011 20

Figure 7: Top Partnersh
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
3. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Access Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference on Monday, September 12th in New York City
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
7. Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force
8. Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets
9. Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
10. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
11. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 /PRNewswire/ ... devices for the transcarotid treatment of intra- and ... Michael P. Wallace to the position ... Michael will lead the company,s Research and Development ... treatment devices. Prior to joining ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... DIEGO, April 20, 2012 /PRNewswire-iReach/ -- Nutrilys ... San Diego, has partnered with the Los Angeles Police ... armor. Nutrilys Del Mar founder, Thierry Lerond, journeyed to Los ... while helping them handpick the world,s best organic, ...
... 2012  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal year 2012 on Tuesday, May 1. ... to discuss its financial results and operating activities, open ...
Cached Medicine Technology:Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit 2Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
(Date:7/23/2014)... July 23, 2014 CarePoint Health is ... hospital in New Jersey to receive the da Vinci® ... platform in the da Vinci series. This 4th generation ... step forward in innovation. The intuitive da Vinci Xi ... wide spectrum of minimally invasive and complex surgical procedures. ...
(Date:7/23/2014)... July 23, 2014 Recently, Agebc.com has ... Now, the company is announcing a promotion of wedding ... promotion will end at the end of this month. ... many popular styles, like A-line, mermaid, ball-gown, empire, and ... dresses and other special-occasion dresses for women, and the ...
(Date:7/23/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on a topic that is quickly ... dialogues: opiate abuse facts. , The Best Drug Rehabilitation blog ... An overview of opiates, and why they’re considered “the mother ...
(Date:7/23/2014)... Europe Drilling fluid and Completion fluid Market Report defines and ... with analysis and forecast of revenue. The drilling fluid and ... around $1.3 billion in 2013 to $1.7 billion by 2018, ... Browse through the TOC of the Europe drilling fluid and ... in-depth analysis provided. This also provides a glimpse of the ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6
... is widely accepted that urgent endoscopy for UGIB should be performed ... time, it is still unclear whether it should be performed either ... more delayed interval, such as after 6, 12 or 24 hour. ... been yet established. , A research article to be published on ...
... Brazos Valley residents,neuroscience researchers, and interested clinicians will ... on the,topic of stroke during the Texas Brain ... 19. This year,s symposium will consist of a,morning ... for clinicians,and researchers. The speakers are both neuroscience ...
... Dialysis Providers, Patient Advocates Work with Local Kidney,Community ... Texas, Sept. 9 With the,highest per capita ... the,Gulf Coast region is bracing to avoid a ... disrupt the administration of,life-saving dialysis treatments to area ...
... 9 Encorium Group, Inc.,(Nasdaq: ENCO ), ... studies in over 30 countries for many of ... that it,has entered into an amendment (the "Amendment") ... Inc. ("Prologue"). Pursuant to the,Amendment, the Company will ...
... Correction of Familial Risk Estimates Increases Estimated Melanoma Risk ... The relative risk of familial melanoma increases substantially when ... large cohort study. The relative risk of familial lung, ... with the correction. , Researchers have used the Swedish ...
... in the United States undergo lung surgery each year, ... their care. In the current issue of The ... proposed a system of lung surgery quality indicators for ... best practices for obtaining positive patient outcomes. , Death ...
Cached Medicine News:Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2Health News:Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 3Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 4Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 5Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 2Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: